Teva And Alvotech Strike US Biosimilars Pact
Deal Covers Five Biosimilar Candidates With $35bn Brand Value
Executive Summary
Teva and Alvotech have announced a major biosimilars alliance covering five products for the US market.
You may also be interested in...
Teva Doubles Down On Alvotech Biosimilars Partnership
Teva will get more involved in Alvotech’s quality oversight as part of enhancements to the pair’s US biosimilars collaboration that will also see two products added to the deal, as well as a $40m investment in Alvotech from the Israeli giant.
Teva Is Committed To Alvotech Alliance – But Would ‘Love’ To Move On Adalimumab ‘Soon’
Teva has spoken of its US biosimilars alliance with Alvotech, in the wake of several major setbacks for the companies’ plans to launch a biosimilar to AbbVie’s Humira (adalimumab) juggernaut on 1 July.
Alvotech’s Simponi Biosimilar Steps Into Phase III RA Study
Alvotech has marked another milestone by moving its proposed biosimilar to Simponi (golimumab) into Phase III comparison studies.